90
80
70
60
50
40
30
20
10
Placebo
61 events/103 patients
median, 18.0 months
[95% CI: 12.1, 24.0]
CLARINET OPEN LABEL EXTENSION STUDY
PFS
(40 patients with stable disease [SD] continuing on lanreotide: LAN-LAN group)
101
84
71
61
51
36
25
17
11
7
5
5
1
0
103
87
59
43
26
0
40 patients with SD while receiving lanreotide in the core study
continued into the Open Label Extension study
Lanreotide Autogel
45 events/101 patients (core: 32 events/101 patients; OLE: 13 events/40 patients)
median, 32.8 months [95% CI: 30.9, 68.0]
Patients Alive and With No Progression, %
Core study
Central radiological assessment
Extension study
Local radiological assessment
100
0
0
6
12
18
24
30
36
42
48
54
60
66
72
78
Time From Randomization in Core Study, months
Caplin M, et al.
Endocr Relat Cancer
2016
